Tacrolimus (graceptor (R)) for GVHD prophylaxis after allogeneic stem cell transplantation

Tacrolimus (graceptor (R)) for GVHD prophylaxis after allogeneic stem cell transplantation - Tacrolimus for GVHD prophylaxis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002441

Enrollment

Registered

2009-10-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, malignant lymphoma

Interventions

tacrolimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have indication of allogeneic stem cell transplantation with tacrolimus for GVHD prophylaxis

Exclusion criteria

Exclusion criteria: Patients who have internal organs dysfunction

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of oral tacrolims	—

Countries

Japan

Contacts

Public ContactShingo Yano

Jikei university school of medicine Clinical Oncology and Hematology

yano@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026